DA
BIIB icon

Dillon & Associates’s Biogen BIIB Stock Holding History

Dillon & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,031
Closed -$293K – 67
2020
Q3 		$293K Sell
1,031
-320
-24% -$89.3K 0.07% 58
2020
Q2 		$362K Hold
1,351
– – 0.1% 53
2020
Q1 		$427K Sell
1,351
-100
-7% -$30.3K 0.14% 52
2019
Q4 		$431K Sell
1,451
-425
-23% -$118K 0.12% 53
2019
Q3 		$437K Sell
1,876
-930
-33% -$217K 0.13% 51
2019
Q2 		$657K Sell
2,806
-60
-2% -$13.9K 0.2% 50
2019
Q1 		$676K Buy
2,866
+45
+2% +$14.2K 0.22% 47
2018
Q4 		$849K Buy
2,821
+105
+4% +$33.5K 0.32% 41
2018
Q3 		$959K Buy
2,716
+95
+4% +$32.7K 0.32% 40
2018
Q2 		$760K Buy
2,621
+397
+18% +$112K 0.28% 43
2018
Q1 		$609K Buy
2,224
+569
+34% +$177K 0.24% 48
2017
Q4 		$528K Buy
1,655
+185
+13% +$59.3K 0.2% 51
2017
Q3 		$460K Buy
1,470
+10
+0.7% +$2.96K 0.18% 53
2017
Q2 		$396K Sell
1,460
-325
-18% -$85.9K 0.16% 56
2017
Q1 		$487K Buy
1,785
+5
+0.3% +$1.41K 0.21% 55
2016
Q4 		$506K Buy
1,780
+40
+2% +$11.9K 0.23% 53
2016
Q3 		$545K Buy
1,740
+60
+4% +$17.8K 0.25% 52
2016
Q2 		$407K Buy
1,680
+245
+17% +$64.6K 0.19% 56
2016
Q1 		$373K Buy
1,435
+265
+23% +$70K 0.17% 56
2015
Q4 		$358K Buy
1,170
+65
+6% +$18.7K 0.17% 55
2015
Q3 		$323K Buy
1,105
+203
+23% +$67K 0.16% 59
2015
Q2 		$364K Buy
902
+157
+21% +$63K 0.18% 54
2015
Q1 		$314K Buy
745
+45
+6% +$17.7K 0.15% 56
2014
Q4 		$237K Sell
700
-45
-6% -$14.6K 0.12% 60
2014
Q3 		$247K Hold
745
– – 0.13% 60
2014
Q2 		$234K Hold
745
– – 0.12% 58
2014
Q1 		$228K Hold
745
– – 0.12% 58
2013
Q4 		$209K Buy
+745
New +$193K 0.11% 59

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dillon & Associates's BIIB Position: Q4 2020 in Review

Dillon & Associates sold out of Biogen (BIIB) in Q4 2020, closing a stake of 1,031 shares — an estimated $293K sold.

Dillon & Associates first reported a position in BIIB in Q4 2013 and held it in 28 quarters. The position peaked at $959K in Q3 2018. 1,061 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

  • Dillon & Associates reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
  • Dillon & Associates sold 1,031 Biogen shares in Q4 2020, an estimated $293K.
  • Dillon & Associates first reported a position in Biogen in Q4 2013 and held it in 28 quarters.
  • Dillon & Associates's Biogen position peaked at $959K in Q3 2018.
  • 1,061 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Dillon & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.